Tuberculosis
IGRAs are in vitro, blood-based assays that involve challenging the immune cells of the body with TB-specific antigens and then measuring the amount of interferon-gamma that is produced by the cells. The rationale is that any cell that recognizes the TB-specific antigens due to prior exposure, will produce interferon-gamma in vitro.
IGRAs are in vitro, blood-based assays that involve challenging the immune cells of the body with TB-specific antigens and then measuring the amount of interferon-gamma that is produced by the cells. The rationale is that any cell that recognizes the TB-specific antigens due to prior exposure, will produce interferon-gamma in vitro.
IGRAs have several advantages over skin tests; a single clinic visit is required, and they generally have high sensitivity and specificity. The WHO has now acknowledged that isolating, washing, counting and standardizing the cells used in IGRA testing can be beneficial, and these steps contribute to test reproducibility and performance.
The T-SPOT.TB test is a unique IGRA that requires only one visit and one tube. Unlike other IGRAs, the T-SPOT.TB test is standardized for both cell number and culture conditions, making it one of the most sensitive and specific tests for TB infection. By standardizing the number of cells and eliminating serum factors that could potentially impact test results, it ensures accuracy and reliability. Physicians can quickly and reliably diagnose TB infection in all patient groups, including the immunosuppressed.
Cytomegalovirus
Cytomegalovirus (CMV) is an opportunistic virus and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant patients. T cell immunity against CMV is an important factor in maintaining viral latency and reducing susceptibility to disease.
Cytomegalovirus (CMV) is an opportunistic virus and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant patients. T cell immunity against CMV is an important factor in maintaining viral latency and reducing susceptibility to disease.
Routine monitoring of an individual’s CMV specific T cell response may assist the evaluation of patients at risk of CMV disease and guide antiviral prophylaxis management.
The T-SPOT.CMV test uses the T-SPOT technology to assess a patient’s level of anti-CMV cell-mediated immunity by isolating and stimulating the immune cells with CMV specific antigens.
SARS-CoV-2
CE marked ror IVD use, the T-SPOT.COVID test is a standardized ELISPOT based technique for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood, intended for use as an aid in identifying and monitoring individuals with a T cell immune response to COVID-19 vaccination or SARS-CoV-2 infection.
CE marked ror IVD use, the T-SPOT.COVID test is a standardized ELISPOT based technique for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood, intended for use as an aid in identifying and monitoring individuals with a T cell immune response to COVID-19 vaccination or SARS-CoV-2 infection.
The test uses the established T-SPOT Technology with an optimized antigen mix, based on SARS-CoV-2 structural proteins, spike (S) and nucleocapsid (N), and allows the maximum breadth of the immune response to be measured.
For research-use only, the T-SPOT Discovery SARS-CoV-2 assay kit is intended to detect COVID-19 cellular mediated immunity using viral peptide pools from SARS-CoV-2. The assay kit is for research use only, and is not intended for diagnostic use in determining infection nor protective immunity towards any of the antigens tested.